In response to legislation that could expedite congressional consideration of the Verifying Accurate Leading-edge IVCT Development (VALID) Act, ASCP has submitted
formal comments urging reconsideration. On May 17, the Senate Health, Education, Labor, and Pensions (HELP) attached the VALID Act to the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act. Adding the VALID Act to this “must pass” bill significantly reduces the likelihood that Congress will make any of the numerous changes sought by the laboratory community.
In our comments on the bill, ASCP urged that the VALID Act be removed from the draft bill so that it can receive thorough review by Congress. ASCP also joined together with
90+ healthcare associations, providers and medical centers in calling on the Senate Committee to remove the VALID Act from FDASLA. In addition, ASCP reissued its Action Alert to its members urging them to contact their Congressional representatives and urge them to oppose the VALID Act’s inclusion in the FDA funding bill. The
Action Alert is still active and ASCP is urging all laboratory professionals, regardless of whether they are ASCP members, to contract their elected representatives about the VALID Act.
To read more articles from this issue of ePolicy, click
here. To learn more about ePolicy News and access past newsletters and articles, click
here.
For more information regarding ASCP's advocacy initiatives and policy positions, please contact ASCP's Center for Public Policy at (202) 408-1110.
ASCP ePolicy News is supported by an unrestricted grant from Hologic.
